Management of Lp(a)

Journal of Clinical Lipidology

Volumn 4, Issue 4, 2010, Pages 240-247

  Brown, W Virgil ^a   Ballantyne, Christie M ^b   Jones, Peter H ^b   Marcovina, Santica ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN B100; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLASMIN; PLASMINOGEN; TRIACYLGLYCEROL; APOLIPOPROTEIN A; LOW DENSITY LIPOPROTEIN;

AFRICAN AMERICAN; ALLELE; AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ANTIGENICITY; ARTERIAL WALL THICKNESS; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BIOTRANSFORMATION; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIET; DISEASE ASSOCIATION; DYSLIPIDEMIA; ESTROGEN THERAPY; FAMILY HISTORY; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MOLECULAR WEIGHT; NOTE; PHYSICIAN; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARDIZATION; STROKE; ARTICLE; CHEMISTRY; GENETICS; METABOLISM; RISK FACTOR; VASCULAR DISEASE;

APOLIPOPROTEINS A; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; PLASMINOGEN; RISK FACTORS; VASCULAR DISEASES;

EID: 78649646814     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.07.002     Document Type: Note

References (14)

1. Berg K. A new serum type system in mandthe Lp system. Acta Pathol Microbiol Scand. 1963;59:369-382.
2. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987;80(2):458-465.
3. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
4. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB. Variation in lipoprotein (a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest. 1993;91(2):443-447.
5. Schreiner PJ, Morrisett JD, Sharrett AR, et al. Lipoprotein(a) as a risk factor for preclinical atherosclerosis. Arterioscler Thromb. 1993;13:826-833.
6. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease.Metaanalysis of prospective studies. Circulation. 2000;102:1082-1085.
7. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000;46:1956-1967.
8. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283:1845-1852.
9. The Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412-423.
10. Jones PJ, Blumenthal R. Lipoprotein(a) measurement and determining risk of myocardial infarction. JAMA. 2009;302:164521645.
11. Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339.
12. Daida H, Lee YJ, Yokoi H, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Am J Cardiol. 1994; 73:1037.
13. Thompson GR, Maher VMG, Matthews S, et al. Familial hypercholesterolemia regression study: A randomized trial of low-density lipoprotein apheresis. Lancet. 1995;345:811.
14. Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein (a) levels and prevent major adverse coronary events. Nat Rev Cardiol. 2009;6:229.